Shaping a UK National Pharmaceutical Strategy

The UK’s pharmaceutical industry is at a pivotal moment. The Labour government’s long-awaited industrial strategy includes a life sciences sector plan, which aims to support investment, streamline regulation and facilitate low-friction procurement. But stringent NHS drug price caps, inefficient rollouts and intense global competition present massive challenges. A long-term, joined-up strategy to connect innovation, commercialisation, manufacturing and access could be critical to secure the UK’s future as a world leader in life sciences. 

Taking place ahead of the Global Pharma and Biotech Summit, this FT Live webinar will discuss how life sciences companies operating in the UK can work with partners in business and government to scale up and drive industry growth. Experts will debate what can be done to make the UK a more competitive hub for investment, improve access to new medicines and ultimately deliver better outcomes for patients. 

What does a UK National Pharmaceutical Strategy need to deliver over the next 10 years, and which gaps must it close?

How can government and industry work together to sharpen the UK’s edge in life sciences research?

How can the industry improve relations with NICE and integration across the NHS? 

What changes are needed to make the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) more sustainable and supportive of innovation? 

Global Pharma and Biotech Summit
11-12 November 2025, London and Online

The Global Pharma and Biotech Summit will bring together C-suite leaders, investors and innovators to assess the forces reshaping healthcare and life sciences. From emerging technologies to shifts in regulation and investment, the event offers critical insights into the future of the sector. Join the conversation in London this autumn.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice